Top

Breast Cancer Research and Treatment

Published in:

01-04-2020 | Breast Cancer | Epidemiology

A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women

Authors: Elodia Rojas-Lima, Brenda Gamboa-Loira, Mariano E. Cebrián, Stephen J. Rothenberg, Lizbeth López-Carrillo

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Abstract

Purpose

To evaluate breast cancer (BC) molecular subtypes association with reproductive characteristics and an index of cumulative exposure to endogenous estrogens (EEI) in Mexican women.

Methods

We performed a study of incident cases and population controls in northern Mexico. We included BC cases with tumor molecular classification in their medical records (n = 509), and classified them as HR+/HER2− (ER+ and/or PR+ and HER2−) (n = 289), HER2+ (HR+ or HR−) (n = 117) or triple negative (TN) (n = 103). We matched controls (n = 1030) by age and place of residence with index cases. Women were interviewed about their reproductive history, from which the EEI was developed. We used logistic regression models to estimate BC molecular subtypes associations with reproductive characteristics and EEI.

Results

The EEI was higher in all subtypes compared to controls (Median HR+/HER2− 27.25, HER2+ 26.8, TN 24.2 vs. controls 22.8 years, p < 0.05), and was associated with HR+/HER2− (OR_T3 vs. T1 = 2.58, 95% CI 1.77–3.55, p-trend < 0.001) and HER2+ (OR_T3 vs. T1 = 4.17, 95% CI 2.15–8.08, p-trend < 0.001) BC. Additionally, HR+/HER2− tumors were positively associated with age at first pregnancy and age at menopause, and negatively with age at menarche, parity and breastfeeding. The HER2+ subtype was associated in the same direction as HR+/HER2− tumors with all the reproductive characteristics except for age at menarche. TN tumors were negatively associated with parity and breastfeeding.

Conclusion

Endogenous estrogens exposure throughout Mexican women reproductive life may contribute to the development of all but TN BC, however, these findings should be confirmed in other Hispanic populations.

Available only for authorised users

Dai X, Xiang L, Li T, Bai Z (2016) Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer 7:1281–1294. https://doi.org/10.7150/jca.13141 CrossRefPubMedPubMedCentral

Blows FM, Driver KE, Schmidt MK et al (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279. https://doi.org/10.1371/journal.pmed.1000279.g003 CrossRefPubMedPubMedCentral

DeSantis CE, Ma J, Goding Sauer A et al (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67:439–448. https://doi.org/10.3322/caac.21412 CrossRefPubMed

Howlader N, Altekruse SF, Li CI et al (2014) US Incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106:dju055. https://doi.org/10.1093/jnci/dju055 CrossRefPubMedPubMedCentral

Romieu I, Biessy C, Carayol M et al (2018) Reproductive factors and molecular subtypes of breast cancer among premenopausal women in Latin America: the PRECAMA study. Sci Rep 8:13109. https://doi.org/10.1038/s41598-018-31393-7 CrossRefPubMedPubMedCentral

Pérez-Rodríguez G, Aranda-Moreno C, Olivares-Corichi IM, Garcia-Sanchez JR (2015) The association of subtypes of breast cancer with tumour characteristics and reproductive factors in 1326 Mexican women. Contemp Oncol (Pozn) 19:462–466. https://doi.org/10.5114/wo.2015.56652 CrossRef

Wirapati P, Sotiriou C, Kunkel S et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65. https://doi.org/10.1186/bcr2124 CrossRefPubMedPubMedCentral

Ma H, Bernstein L, Pike MC, Ursin G (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8:R43. https://doi.org/10.1186/bcr1525 CrossRefPubMedPubMedCentral

Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 103:250–263. https://doi.org/10.1093/jnci/djq526 CrossRefPubMed

10.

Sisti JS, Collins LC, Beck AH et al (2016) Reproductive risk factors in relation to molecular subtypes of breast cancer: results from the Nurses’ Health Studies HHS Public Access. Int J Cancer 138:2346–2356. https://doi.org/10.1002/ijc.29968 CrossRefPubMedPubMedCentral

11.

Holm J, Eriksson L, Ploner A et al (2017) Assessment of breast cancer risk factors reveals subtype heterogeneity. Cancer Res 77:3708–3717. https://doi.org/10.1158/0008-5472.CAN-16-2574 CrossRefPubMed

12.

Lambertini M, Santoro L, Del Mastro L et al (2016) Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies. Cancer Treat Rev 49:65–76. https://doi.org/10.1016/j.ctrv.2016.07.006 CrossRefPubMed

13.

Ellingjord-Dale M, Vos L, Tretli S et al (2017) Parity, hormones and breast cancer subtypes: results from a large nested case–control study in a national screening program. Breast Cancer Res 19:10. https://doi.org/10.1186/s13058-016-0798-x CrossRefPubMedPubMedCentral

14.

Sweeney C, Baumgartner KB, Byers T et al (2008) Reproductive history in relation to breast cancer risk among Hispanic and non-Hispanic white women. Cancer Causes Control 19:391–401. https://doi.org/10.1007/s10552-007-9098-1 CrossRefPubMed

15.

Phipps AI, Malone KE, Porter PL et al (2008) Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 113:1521–1526. https://doi.org/10.1002/cncr.23786 CrossRefPubMed

16.

Jasienska G, Bribiescas RG, Furberg AS et al (2017) Human reproduction and health: an evolutionary perspective. Lancet 390:510–520. https://doi.org/10.1016/S0140-6736(17)30573-1 CrossRefPubMed

17.

Hammond MEH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. https://doi.org/10.1200/JCO.2009.25.6529 CrossRefPubMedPubMedCentral

18.

Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast: American Society of Clinical Oncology/College of American Pathologist Clinical Practice Guideline Update. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/JCO.2013.50.9984 CrossRefPubMed

19.

López-Carrillo L, Hernández-Ramírez RU, Gandolfi AJ et al (2014) Arsenic methylation capacity is associated with breast cancer in Northern Mexico. Toxicol Appl Pharmacol 280:53–59. https://doi.org/10.1016/j.taap.2014.07.013 CrossRefPubMed

20.

Li H, Sun X, Miller E et al (2017) BMI, reproductive factors, and breast cancer molecular subtypes: a case–control study and meta-analysis. J Epidemiol 27:143–151. https://doi.org/10.1016/j.je.2016.05.002 CrossRefPubMed

21.

Girgert R, Emons G, Gründker C (2019) Estrogen signaling in ERα-negative breast cancer: ERβ and GPER. Front Endocrinol (Lausanne). https://doi.org/10.3389/fendo.2018.00781 CrossRef

22.

Li Y, Birnbaumer L, Teng CT (2010) Regulation of ERRa gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by G protein-coupled receptor GPR30/GPER-1. Mol Endocrinol 24:969–980. https://doi.org/10.1210/me.2009-0148 CrossRefPubMedPubMedCentral

23.

Deblois G, Chahrour G, Perry MC et al (2010) Transcriptional control of the ERBB2 amplicon by ERRa and PGC-1b promotes mammary gland tumorigenesis. Cancer Res 70:10277–10287. https://doi.org/10.1158/0008-5472.CAN-10-2840 CrossRefPubMed

24.

Dittrich A, Gautrey H, Browell D, Tyson-Capper A (2014) The HER2 signaling network in breast cancer: like a spider in its web. J Mammary Gland Biol Neoplasia 19:253–270. https://doi.org/10.1007/s10911-014-9329-5 CrossRefPubMed

25.

Culig Z (2019) Epithelial mesenchymal transition and resistance in endocrine-related cancers. Biochim Biophys Acta Mol Cell Res 1866:1368–1375. https://doi.org/10.1016/j.bbamcr.2019.05.003 CrossRefPubMed

26.

Wallace TR, Tarullo SE, Crump LS, Lyons TR (2019) Studies of postpartum mammary gland involution reveal novel pro-metastatic mechanisms. J Cancer Metastasis Treat. https://doi.org/10.20517/2394-4722.2019.01 CrossRefPubMedPubMedCentral

27.

Russo J, RussoIrma H (2004) Development of the human breast. Maturitas 49:2–15. https://doi.org/10.1016/j.maturitas.2004.04.011 CrossRefPubMed

28.

Merrill RM, Fugal S, Novilla LB, Raphael MC (2005) Cancer risk associated with early and late maternal age at first birth. Gynecol Oncol 96:583–593. https://doi.org/10.1016/j.ygyno.2004.11.038 CrossRefPubMed

29.

Elshmay WM (2016) The protective effect of longer duration of breastfeeding against pregnancy-associated triple negative breast cancer. Oncotarget 7:53941–53950PubMedCentral

30.

Gaudet MM, Gierach GL, Carter BD et al (2018) Pooled analysis of nine cohorts reveals breast cancer risk factors by tumor molecular subtype. Cancer Res 78:6011–6021. https://doi.org/10.1158/0008-5472.CAN-18-0502 CrossRefPubMedPubMedCentral

31.

Park B, Choi J-Y, Sung HK et al (2016) Attribution to heterogeneous risk factors for breast cancer subtypes based on hormone receptor and human epidermal growth factor 2 receptor expression in Korea. Medicine (Baltimore) 95:e3063. https://doi.org/10.1097/MD.0000000000003063 CrossRef

32.

Xing P, Li J, Jin F (2010) A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol 27:926–931. https://doi.org/10.1007/s12032-009-9308-7 CrossRefPubMed

33.

Phipps AI, Chlebowski RT, Prentice R et al (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103:470–477. https://doi.org/10.1093/jnci/djr030 CrossRefPubMedPubMedCentral

34.

Islam T, Matsuo K, Ito H et al (2012) Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women. Ann Oncol 23:2435–2441. https://doi.org/10.1093/annonc/mdr613 CrossRefPubMed

35.

Dolle JM, Daling JR, White E et al (2009) Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18:1157–1166. https://doi.org/10.1158/1055-9965.EPI-08-1005 CrossRefPubMedPubMedCentral

36.

Gaudet MM, Press MF, Haile RW et al (2011) Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 130:587–597. https://doi.org/10.1007/s10549-011-1616-x CrossRefPubMedPubMedCentral

37.

Li CI, Beaber EF, Tang MTC et al (2013) Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age. Breast Cancer Res Treat 137:579–587. https://doi.org/10.1007/s10549-012-2365-1 CrossRefPubMed

38.

Scaling AL, Prossnitz ER, Hathaway HJ (2014) GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm Cancer 5:146–160. https://doi.org/10.1007/s12672-014-0174-1 CrossRefPubMedPubMedCentral

39.

Faupel-Badger JM, Arcaro KF, Balkam JJ et al (2013) Postpartum remodeling, lactation, and breast cancer risk: summary of a National Cancer Institute-Sponsored Workshop. J Natl Cancer Inst 105:166–174. https://doi.org/10.1093/jnci/djs505 CrossRefPubMed

40.

Ma H, Wang Y, Sullivan-Halley J et al (2010) Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women’s contraceptive and reproductive experiences study. Cancer Res 70:575–587. https://doi.org/10.1158/0008-5472.CAN-09-3460 CrossRefPubMedPubMedCentral

41.

Instituto Nacional de Estadística y Geografía (2010) Encuesta Nacional de la Dinámica Demográfica 2009. Metodología y tabulados básicos. Aguascalientes

Title: A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women
Authors: Elodia Rojas-Lima
Brenda Gamboa-Loira
Mariano E. Cebrián
Stephen J. Rothenberg
Lizbeth López-Carrillo
Publication date: 01-04-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Estrogens
Published in: Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05562-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women’s Health Initiative

HER2-positivity in mucinous cancer might be related to accompanying infiltrating ductal carcinoma histology

Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy

The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer

Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer